GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
With the approval of Elunate (fruquintinib), China not only has a promising new option for colorectal cancer (CRC), a disease diagnosed in around 380,000 new Chinese people each year. 5 September 2018
A US-based former GlaxoSmithKline scientist has pled guilty to a charge of leaking trade secrets, two years after authorities filed a complaint. 5 September 2018
In a record 10 days after the drugs approval in Europe, NHS England has agreed that a groundbreaking new personalized CAR-T therapy can be made available to patients. 5 September 2018
Californian biotech firms Gilead Sciences and Trianni have entered into a license agreement to leverage the latter’s proprietary drug discovery platform. 5 September 2018
Shares in Californian biopharma MannKind Corporation closed 89% up on Tuesday as markets reacted to its licensing deal with biotech company United Therapeutics Corporation. 5 September 2018
Family-owned drugmaker Boehringer Ingelheim has agreed a broad collaboration with Beijing-based Tsinghua University to research and develop immunological therapies for infectious diseases. 5 September 2018
USA-based Merck has won priority review in the USA for a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab). 4 September 2018
Janssen has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a drug that could offer something new in a therapy area that is pining for disruption. 4 September 2018
Though being vague on terms, and not naming the collaboration partner for a new licensing deal, UK life sciences firm OptiBiotix Health saw its shares, which had already risen 72% in the year to date, gain a further 6.5% to 105.97 pence by early afternoon trading today. 4 September 2018
Oxford University biotech spinout Evox Therapeutics has raised £35.5 million ($45.4 million) in a series B financing round, with new money from Google’s venture capital unit GV, and Cowen Healthcare Investments. 3 September 2018
Promore Pharma, a Swedish developer of therapeutic peptides, plans to expand the indications of its lead compound, the anti-adhesion and anti-scarring agent PXL01, to explore the feasibility of using the compound for the prevention of dermal scarring. 3 September 2018
Before joining Boston University to study biomedical engineering and chemistry, Mass Innovation Labs founder Amrit Chaudhuri was the youngest paid researcher at the MIT-affiliated Whitehead Institute for Biomedical Research, at age 15. 3 September 2018
French pharma major Sanofi has been granted EU approval to market Cablivi (caplacizumab) for episodes of a rare and life-threatening genetic disorder, acquired thrombotic thrombocytopenic purpura (aTTP). 3 September 2018
Danish biotech Genmab and its commercialization partner Janssen Biotech promise sales of Darzalex (daratumumab) in the front-line setting will start soon after the European Commission (EC) gave it the green light. 31 August 2018
A new study comparing Roche’s Lucentis (ranibizumab) with the firm’s own Avastin (bevacizumab) and Bayer's Eylea (aflibercept) supports Lucentis as a safe and effective therapy for the treatment of wet age-related macular degeneration (AMD). 31 August 2018
Some 12 years after the drug’s first US Food and Drug Administration (FDA) approval in leukemia, Bristol-Myers Squibb is still targeting new patients with Sprycel (dasatinib). 31 August 2018
In a disappointment for the company, Pfizer has scrapped the development of a potential Duchenne muscular dystrophy (DMD) candidate, a therapeutic area that the US pharma giant only entered in early 2015. 31 August 2018
Czech biotech firm SOTIO, part of the the privately-owned PPF Group, has completed the acquisition of Cytune Pharma, a firm developing IL-15 based therapies for the treatment of cancer, for an undisclosed sum. 30 August 2018
Weeks after a landmark approval in the USA, Alnylam Pharmaceuticals’ RNA interference (RNAi) therapeutic has been approved by the European Commission (EC). 30 August 2018
There was positive news today for Germany’s largest pharma company, with approval for its latest hemophilia A drug in the USA, which hopefully will provide a near term boost to its hemophilia portfolio. 30 August 2018